Effects of losartan on cerebral and ocular circulation in healthy subjects

被引:32
作者
Matulla, B
Streit, G
Pieh, S
Findl, O
Entlicher, J
Graselli, U
Eichler, HG
Wolzt, M
Schmetterer, L
机构
[1] DEPT CLIN PHARMACOL, A-1090 VIENNA, AUSTRIA
[2] DEPT OPHTHALMOL B, A-1090 VIENNA, AUSTRIA
[3] INST MED PHYS, A-1090 VIENNA, AUSTRIA
关键词
Doppler sonography; fundus pulsation; losartan; angiotensin II; cerebral blood flow; ocular blood flow;
D O I
10.1046/j.1365-2125.1997.t01-1-00598.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The introduction of specific inhibitors of AT(1) receptors, such as losartan, has enabled the investigation of the renin-angiotensin-system (RAS) in humans in vivo. We studied the role of the RAS in the cerebral and ocular circulation in healthy subjects. Haemodynamic effects of orally administered losartan were investigated with non-invasive methods. Methods In a placebo-controlled randomized, double-blind two way crossover design losartan (100 mg orally) or placebo was administered in 10 healthy subjects. The effect of losartan was studied at hourly intervals for 8 h. In addition, the effect of losartan on haemodynamic changes induced by exogenous angiotensin II (Ang II) was assessed. Blood flow velocities in the ophthalmic and the middle cerebral artery (OA, MCA) were measured with Doppler sonography. Pulsatile choroidal blood flow was estimated with laser interferometric measurement of fundus pulsation. Results Losartan significantly increased fundus pulsation amplitude (+11%, 95% CI: 5 to 16% P < 0.0001), tended to increase resistive index in the ophthalmic artery (+12%, 95% CI: 0 to 23%) and tended to decrease mean arterial pressure (-15%, 95% CI: -23 to -1%). Ang II induced effects on cerebral, ocular and systemic haemodynamics were prevented by preceding administration of losartan. Conclusions The present data suggest that Ang II is not a major determinant of cerebral and ocular blood flow in vivo. The observed changes in cerebral and ocular haemodynamic parameters after losartan administration reflect effects on systemic blood pressure.
引用
收藏
页码:369 / 375
页数:7
相关论文
共 38 条
[1]   NON-INVASIVE TRANSCRANIAL DOPPLER ULTRASOUND RECORDING OF FLOW VELOCITY IN BASAL CEREBRAL-ARTERIES [J].
AASLID, R ;
MARKWALDER, TM ;
NORNES, H .
JOURNAL OF NEUROSURGERY, 1982, 57 (06) :769-774
[2]   EFFECTS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITION - A CLINICAL POINT OF VIEW [J].
BRUNNER, HR ;
NUSSBERGER, J ;
WAEBER, B .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 :S73-S81
[3]   ORAL-ADMINISTRATION OF DUP-753, A SPECIFIC ANGIOTENSIN-II RECEPTOR ANTAGONIST, TO NORMAL-MALE VOLUNTEERS - INHIBITION OF PRESSOR-RESPONSE TO EXOGENOUS ANGIOTENSIN-I AND ANGIOTENSIN-II [J].
CHRISTEN, Y ;
WAEBER, B ;
NUSSBERGER, J ;
PORCHET, M ;
BORLAND, RM ;
LEE, RJ ;
MAGGON, K ;
SHUM, L ;
TIMMERMANS, PBMWM ;
BRUNNER, HR .
CIRCULATION, 1991, 83 (04) :1333-1342
[4]  
Costagliola C, 1995, Eur J Ophthalmol, V5, P19
[5]   EFFECTS OF AN ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR, RAMIPRIL, ON INTRACRANIAL CIRCULATION IN HEALTHY-VOLUNTEERS [J].
DEMOLIS, P ;
CHALON, S ;
ANNANE, D ;
DUHAZE, P ;
GIUDICELLI, JF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :224-230
[6]   EFFECTS OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR, LISINOPRIL, ON CEREBRAL BLOOD-FLOW AUTOREGULATION IN HEALTHY-VOLUNTEERS [J].
DEMOLIS, P ;
CARVILLE, C ;
GIUDICELLI, JF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (03) :373-380
[7]   EFFECTS OF ANGIOTENSIN-II ON CEREBRAL BLOOD-VESSELS [J].
EDVINSSON, L ;
HARDEBO, JE ;
OWMAN, C .
ACTA PHYSIOLOGICA SCANDINAVICA, 1979, 105 (03) :381-383
[8]  
FERRARIDILEO G, 1991, INVEST OPHTH VIS SCI, V32, P21
[9]   LOSARTAN PROTECTIVE EFFECTS IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS PERSIST DURABLY AFTER TREATMENT WITHDRAWAL [J].
FORNES, P ;
RICHER, C ;
VACHER, E ;
BRUNEVAL, P ;
GIUDICELLI, JF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 (02) :305-313
[10]   Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men [J].
Goldberg, MR ;
deMey, C ;
Wroblewski, JM ;
Li, Q ;
Schroeter, V ;
Belz, GG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :72-82